Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fidrisertib - Ipsen

Next Previous
Drug Profile

Fidrisertib - Ipsen

Alternative Names: BLU-782; IPN-60130

Latest Information Update: 30 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Blueprint Medicines
  • Developer Ipsen
  • Class Carbamates; Furans; Piperazines; Piperidines; Pyridazines; Pyridines; Pyrroles; Small molecules
  • Mechanism of Action ACVR1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fibrodysplasia ossificans progressiva
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Fibrodysplasia ossificans progressiva

Most Recent Events

  • 19 Dec 2025 Ipsen terminates phase II clinical trials in Fibrodysplasia ossificans progressiva (In adolescents, In children, In the elderly, In adults) in Germany, the Netherlands, Italy, Spain, Sweden, United Kingdom, USA, Argentina, Australia, Belgium, Canada, China, France, Japan, South Korea, Mexico, Portugal (NCT05039515) (EudraCT2020-002858-24)
  • 18 Jul 2025 Blueprint Medicines has been acquired by Sanofi
  • 01 Dec 2021 Phase-II clinical trials in Fibrodysplasia ossificans progressiva (In adolescents, In children, In the elderly, In adults) in Germany, Netherlands, Spain, United Kingdom, USA (PO) after December 2021 (NCT05039515) (EudraCT2020-002858-24)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top